- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05616949
Peer Recovery Support Services for Individuals in Recovery Residences on MOUD
The United States is experiencing an unprecedented opioid epidemic with a rapid increase in overdose deaths. Medications for opioid use disorder (MOUD) including methadone, buprenorphine, and extended-release naltrexone are efficacious and the recommended standard of care, yet barriers to sustained MOUD treatment reduce the overall efficacy of MOUD. Rates of MOUD retention are alarmingly low and MOUD dropout predicts opioid use/relapse, overdose, and death. While previous research has identified predictors of MOUD retention and adherence, there are no evidence-based interventions to improve MOUD retention.
Recovery support services are a broad set of strategies to promote healthy outcomes among individuals with substance use disorder (SUD) that are typically separate from standard professional treatment. Among those strategies most utilized are peer recovery support services (PRSS) and recovery residences (RRs). PRSS include coaching, mentoring, education, and other supports delivered by individuals uniquely qualified by their lived experience with SUD. PRSS are increasingly utilized in a range of clinical settings, and advantages of PRSS include inherent shared understanding of addiction and a high degree of acceptance and understanding that is not found in most professional relationships. Existing research tentatively supports PRSS; however, the evidence to date is sparse and comes with significant methodological limitations and inconsistencies that make it difficult to conclude the efficacy of PRSS. No studies have examined the role of PRSS in promoting retention in MOUD. RRs provide a supportive living environment for persons in recovery from SUD and are widely utilized in the United States with an estimated 17,943 residences in 2020. Despite their proliferation, the evidence for RRs is only moderate and diminished by methodological weaknesses. Further, individuals on MOUD seeking housing through RRs often face increased MOUD-related stigma or may be disqualified from a RR for taking MOUD and need additional support to navigate these challenges.
The potential synergistic benefits of combining PRSS and RRs to improve MOUD retention are considerable. PRSS and RRs are already mainstays in the recovery support services repertoire and could be leveraged to support MOUD retention. For example, more frequent, informal outreach typical of PRSS could facilitate regular monitoring of shifting attitudes and behaviors related to MOUD. The structure and accountability embedded in RRs could be used to support MOUD adherence and retention. Waxing and waning motivation to participate in MOUD treatment is common, and standard treatment is often unsuccessful at identifying early signs of future dropout or facilitating re-engagement after dropout.
We will recruit participants on MOUD in RRs and provide them with PRSS using approaches such as recovery coaching and care navigation with a particular focus on supporting retention in MOUD care. PRSS will also provide assertive outreach between episodes of care, emphasize continuation in treatment and other recovery activities after leaving a RR (either successfully or unsuccessfully), and emphasize return to care after treatment dropout and/or relapse. The peers will be deeply embedded within the local provider community and care continuum to facilitate ease of care navigation. The ultimate goal of our research agenda is to test the efficacy of a PRSS intervention among individuals with OUD living in RRs through a rigorous trial. The eventual trial design would be informed by preparatory activities and experience proposed in this planning project.
Preparatory activities proposed in this project include three major phases. Phase 1 - preparation for the intervention including: building a network of RRs that will be recruitment sites in the pilot RCT, recruiting and training peer support specialists, conducting focus groups and interviews to gather stakeholder input, and developing PRSS approaches to promote MOUD retention. Phase 2 - pilot test the PRSS intervention by randomizing N=50 individuals on MOUD recruited from collaborating RRs to either: a 24-week course of the PRSS intervention added to usual services, or usual services without the PRSS intervention. Phase 3 - gather additional input from former participants and RR staff post-intervention to further refine the intervention, and use lessons learned to inform our trial design and data collection procedures for the next-step R01 application.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kevin R. Wenzel, Ph.D.
- Phone Number: 410-233-1400
- Email: kwenzel@marylandtreatment.org
Study Contact Backup
- Name: Marc J. Fishman, M.D.
- Phone Number: 410-233-1400
- Email: Mfishman@marylandtreatment.org
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21229
- Recruiting
- Maryland Treatment Centers
-
Contact:
- Kevin Wenzel, PhD
- Phone Number: 410-233-1400
- Email: kwenzel@marylandtreatment.org
-
Rockville, Maryland, United States, 20853
- Recruiting
- Maryland Treatment Centers/Avery Road Treatment Center
-
Contact:
- Kevin Wenzel, PhD
- Phone Number: 410-233-1400
- Email: kwenzel@marylandtreatment.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18+ (inclusive); meets diagnostic criteria for OUD; residing at a RR affiliated with this study; seeking treatment with and successfully inducted onto MOUD (i.e., XR-NTX, SL-BUP, XR-BUP, or methadone); English speaking; willing and able to provide informed consent.
Exclusion Criteria:
- Currently receiving formalized PRSS outside of the study (not applicable to peer support typical of sponsorship in 12-step mutual support programs or informal support through RRs).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1 Title: Treatment as Usual (TAU)
Arm 1: Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence.
This arm serves as the active comparator group for the study.
|
Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence.
This arm serves as the active comparator group for the study.
|
Experimental: Arm 2 Title: Peer Recovery Support Services (PRSS) + TAU
Arm 2: Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention.
This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services (TAU+PRSS) vs. an active comparator composed of treatment as usual services without the PRSS intervention (i.e., TAU-alone).
Follow ups will be conducted at weeks 2, 4, 8, 12, 16, 20, 24 (end of intervention), 36, and 52 to collect data on the primary outcome of MOUD retention and other outcomes.
|
Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention.
This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cumulative MOUD retention
Time Frame: Cumulative MOUD Retention is the proportion of days on MOUD at 24-weeks (end of intervention period).
|
Primary Outcome: Cumulative MOUD retention on all follow-up assessments for the following data sources: 1) Time Line Follow Back; 2) the Maryland PDMP; and 3) Patient Health Records.
|
Cumulative MOUD Retention is the proportion of days on MOUD at 24-weeks (end of intervention period).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Outcome 1- continuous MOUD retention ("yes" or "no")
Time Frame: Participants who are continuously retained have no gaps in MOUD exceeding 14-days.
|
Continuous MOUD retention on all follow-up assessments will be tracked for the following data sources: 1) Time Line Follow Back; 2) the Maryland PDMP; and 3) Patient Health Records.
|
Participants who are continuously retained have no gaps in MOUD exceeding 14-days.
|
Secondary Outcome 2- opioid relapse ("yes" or "no")
Time Frame: Relapse is defined as ten days of use within a 4-week period.
|
Opioid relapse are measured by tracking responses on the following data sources: Time Line Follow Back.
|
Relapse is defined as ten days of use within a 4-week period.
|
Secondary Outcome 3- re-initiation of MOUD after dropout ("yes" or "no")
Time Frame: Re-initiation of MOUD is defined as re-initiation onto any MOUD for at least 7 days after MOUD dropout (defined as >14 days without MOUD).
|
Re-initiation of MOUD after dropout will be measured by examining all follow-up assessments after dropout for the following data sources: 1) Time Line Follow Back; 2) the Maryland PDMP; and 3) Patient Health Records.
|
Re-initiation of MOUD is defined as re-initiation onto any MOUD for at least 7 days after MOUD dropout (defined as >14 days without MOUD).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kevin R. Wenzel, Ph.D., Mountain Manor Treatment Center - Maryland Treatment Centers
- Principal Investigator: Marc J. Fishman, M.D., Mountain Manor Treatment Center - Maryland Treatment Centers
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R34DA057627-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Use Disorder
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use Disorder | Cocaine Use DisorderUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Woebot HealthNational Institute on Drug Abuse (NIDA); Stanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
University of Wisconsin, MadisonRevive Therapeutics, Ltd.RecruitingSubstance-Related Disorders | Chemically-Induced Disorders | Substance Use Disorders | Methamphetamine Use Disorder | Stimulant-Use DisorderUnited States
-
VA Office of Research and DevelopmentCompletedAntisocial Personality Disorder | Substance Use DisorderUnited States
-
Mclean HospitalNational Institute on Drug Abuse (NIDA)CompletedSchizophrenia | Schizoaffective Disorder | Tobacco Use | Bipolar Disorder | Cannabis | Substance Use | Substance Use Disorders | Psychosis | Alcohol Use Disorder | Mental Disorder | Cigarette Smoking | Nicotine Use Disorder | Family | Marijuana | AlcoholUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
Clinical Trials on Treatment as Usual (TAU) (Arm 1)
-
Centro Mente Aberta de MindfulnessUnknown
-
Academisch Medisch Centrum - Universiteit van Amsterdam...KU Leuven; ZonMw: The Netherlands Organisation for Health Research and Development and other collaboratorsRecruiting
-
Hospital Universitari Vall d'Hebron Research InstituteParc Sanitari Sant Joan de Déu; Universitat Autonoma de BarcelonaCompleted
-
Centre for Addiction and Mental HealthCompleted
-
Nova Scotia Health AuthorityCompletedEating DisordersCanada
-
Virginia Commonwealth UniversityCompletedSubstance Use Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Drug Dependence | Drug Use Disorders | Substance AddictionUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteActive, not recruiting
-
University of BariUniversity of Dublin, Trinity CollegeCompletedRecovery | Mental Disorder | Schizophrenia and Related Disorders | Intellectual Disability, Mild to Moderate | Personality Disorders and Disturbances in Behavior | Personality Disorders, AntisocialItaly
-
Fundació Sant Joan de DéuUniversitat Autonoma de BarcelonaRecruiting
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedSubstance AbuseUnited States